Despite having the highest rates of cannabis use in the continent, France enforces the most repressive laws against the drug in all of Europe. Perhaps surprisingly, France was once the epicentre of a global movement to medicalize cannabis, specifically hashish, in the treatment of disease. In Taming Cannabis David Guba examines how nineteenth-century French authorities routinely blamed hashish consumption, especially among Muslim North Africans, for behaviour deemed violent and threatening to the social order. This association of hashish with violence became the primary impetus for French pharmacists and physicians to tame the drug and deploy it in the homeopathic treatment of mental illness and epidemic disease during the 1830s and 1840s. Initially heralded as a wonder drug capable of curing insanity, cholera, and the plague, hashish was deemed ineffective against these diseases and fell out of repute by the middle 1850s. The association between hashish and Muslim violence, however, remained and became codified in French colonial medicine and law by the 1860s: authorities framed hashish as a significant cause of mental illness, violence, and anti-state resistance among indigenous Algerians. As the French government looks to reform the nation's drug laws to address the rise in drug-related incarceration and the growing popular demand for cannabis legalization, Taming Cannabis provides a timely and fascinating exploration of the largely untold and living history of cannabis in colonial France.

Despite having the highest rates of cannabis use in the continent, France enforces the most repressive laws against the drug in all of Europe. Perhaps surprisingly, France was once the epicentre of a global movement to medicalize cannabis, specifically hashish, in the treatment of disease. In Taming Cannabis David Guba examines how nineteenth-century French authorities routinely blamed hashish consumption, especially among Muslim North Africans, for behaviour deemed violent and threatening to the social order. This association of hashish with violence became the primary impetus for French pharmacists and physicians to tame the drug and deploy it in the homeopathic treatment of mental illness and epidemic disease during the 1830s and 1840s. Initially heralded as a wonder drug capable of curing insanity, cholera, and the plague, hashish was deemed ineffective against these diseases and fell out of repute by the middle 1850s. The association between hashish and Muslim violence, however, remained and became codified in French colonial medicine and law by the 1860s: authorities framed hashish as a significant cause of mental illness, violence, and anti-state resistance among indigenous Algerians. As the French government looks to reform the nation's drug laws to address the rise in drug-related incarceration and the growing popular demand for cannabis legalization, Taming Cannabis provides a timely and fascinating exploration of the largely untold and living history of cannabis in colonial France.

Focussing on the ways in which cannabis has been demonized, sacralized and normalized, Christopher Partridge analyses the complex and often difficult relationship Western societies have had with the plant since the nineteenth century. After an introduction to cannabis and its uses, the book discusses how and why it was constructed as a profane influence and a marker of deviance. It then examines the emergence of medicinal cannabis, showing how this has contributed to its normalization and even its sacralization. Finally, there is a discussion of sacred cannabis, which looks at its use within modern occultism, Rastafari and several cannabis churches. Overall, the book provides a cultural history of cannabis in the modern world, which exposes the underlying reasons for the various and changing attitudes to this popular psychoactive substance.

In the nineteenth century, drug consumption permeated French society to produce a new norm: the chemical enhancement of modern life. French citizens empowered themselves by seeking pharmaceutical relief for their suffering and engaging in self-medication. Doctors and pharmacists, meanwhile, fashioned themselves as gatekeepers to these potent drugs, claiming that their expertise could shield the public from accidental harm. Despite these efforts, the unanticipated phenomenon of addiction laid bare both the embodied nature of the modern self and the inherent instability of the notions of individual free will and responsibility. Drugging France explores the history of mind-altering drugs in medical practice between 1840 and 1920, highlighting the intricate medical histories of opium, morphine, ether, chloroform, cocaine, and hashish. While most drug histories focus on how drugs became regulated and criminalized as dangerous addictive substances, Sara Black instead traces the spread of these drugs through French society, demonstrating how new therapeutic norms and practices of drug consumption transformed the lives of French citizens as they came to expect and even demand pharmaceutical solutions to their pain. Through self-experimentation, doctors developed new knowledge about these drugs, transforming exotic botanical substances and unpredictable chemicals into reliable pharmaceutical commodities that would act on the mind and body to modify pain, sensation, and consciousness. From the pharmacy counter to the boudoir, from the courtroom to the operating theatre, from the battlefield to the birthing chamber, Drugging France explores how everyday encounters with drugs reconfigured how people experienced their own minds and bodies.

Cannabis is one of the oldest cultivated plants dating back 12,000 years and demonstrates medicinal properties including immune support, anti-inflammatory effects, and cancer-fighting potential. As cannabis receives regulatory approval in the United States, clinicians will need guidelines to prescribe medical marijuana for various health conditions. This book presents information to healthcare professionals focusing on medical cannabis. It is a science-based overview providing clinical recommendations and dosing guidelines for practitioners to advise patients appropriately. Features: Discusses the endocannabinoid system role in homeostasis, pain control, and regulatory function in health and disease Advises clinicians on cannabis use in patients with cancer; cardiovascular, brain, and liver function; mood disorders; and patients receiving palliative care Includes information on cannabis nutrition as well as the cannabis microbiome Features information on cannabis quality control for safe and effective delivery Cannabis: A Clinician’s Guide is written for clinicians providing a resource guide to help them assess the medicinal value of cannabis, answer patient and consumer questions, and recommend its use optimally. The book is divided into three sections covering cannabis science, use in clinical practice, and regulations and standards. It includes practical information on dosing guidelines and dispensary insights, personal cannabis stories, and an in depth look at the nutritional benefits of cannabis and how to use it in daily life. From the Author: "As a clinical nutritionist, I have been involved in the use of cannabis since 1981 while researching diabetes in India. Ayurvedic medicine listed cannabis as a beneficial herb with curing properties. In 1983, a Chinese medicine doctor in the Peoples Republic of China gave me a cannabis herbal supplement for sleep that he claimed Chairman Mao took regularly. Upon returning to the United States, no one would even talk to me about cannabis because of its Schedule I status. During an Antioxidants class taught for Everglades University, I included information on cannabis, but was restricted from including it in the course description. Cannabis: A Clinician’s Guide unveils deceit on this herbal medicine used for thousands of years providing insight into the science behind its use and how to incorporate cannabis into daily life, especially for those suffering from neurological disorders, cancer, and mood disorders."

The Yearbook of Transnational History is dedicated to disseminating pioneering research in the field of transnational history. This fifth volume advances the frontier of transnational history into early modern times. The six chapters of this volume explore topics and themes from early modern times to the fall of Communism. This volume includes chapters about the Huguenots and Sephardi Jews as transnational nations in the seventeenth and eighteenth century, the construction of cannabis knowledge cultures in the transatlantic world of the nineteenth century, the role of the German pastor Martin Niemoeller in the construction of transnational religious identities in the aftermath of World War II, and the labor migration - from Cuba to East Germany - within the Socialist world in the 1970s and 1980s.

Cannabis consumption, commerce, and control in global history, from the nineteenth century to the present day. This book gathers together authors from the new wave of cannabis histories that has emerged in recent decades. It offers case studies from Africa, Asia, the Americas, Europe, and the Middle East. It does so to trace a global history of the plant and its preparations, arguing that Western colonialism shaped and disseminated ideas in the nineteenth century that came to drive the international control regimes of the twentieth. More recently, the emergence of commercial interests in cannabis has been central to the challenges that have undermined that cannabis consensus. Throughout, the determination of people around the world to consume substances made from the plant has defied efforts to stamp them out and often transformed the politics and cultures of using them. These texts also suggest that globalization might have a cannabis history. The migration of consumers, the clandestine networks established to supply them, and international cooperation on control may have driven much of the interconnectedness that is a key feature of the contemporary world.

The cultural, scientific and legislative divide created by vigorous debates over the legalization of medical marijuana is giving way to a new synergy among community stakeholders across the United States. The goal is to improve access to medical marijuana for patients with refractory debilitating neurological disorders, cancer, and chronic pain as an alternative to ineffective pharmacotherapy and potentially addictive pain medications. The ultimate test of our nations resolve to ensure the welfare of our sickest patients is the enactment and implement of effective public health reform in the area of medical marijuana, also known as medical cannabis.This book evolved out of the present need for a definitive volume on the science and public health aspects of medical cannabis to fuel this national narrative. The ethnographic research presented in the concluding chapter was inspired by Professor Miriam W. Boeri and colleagues, at Bentley University in Waltham, MA. They examined views of community stakeholders including medical marijuana dispensary entrepreneurs, health care professionals, and patients in a state that legalized medical marijuana in 2013, yet there continued to be confusion and misunderstandings in the interpretation and implementation of medical marijuana guidelines during the period of policy shifts. Apparent gaps in policy development and implementation signaled the urgency for a comparison study addressing stakeholder views in New York State, where its medical marijuana program has legally dispensed the drug since 2014. The resulting pilot study was carried out in the Division of Health Policy and Management of the City University of New York School of Public Health. The research model incorporated ethnographic and grounded methodologies to detail the views of physicians, pharmacists, educators, patients, and entrepreneur stakeholders; with triangulation of data and application of dominant themes into a socioecological framework model to identify areas of public health policy reform. The findings of this study detail that New York, like other states that recently legalized the dispensation of medical marijuana, faces challenges beyond policy transparency, communication and education explicitly to improve the implementation process for applying and registering medical cannabis dispensaries, referring physicians, and qualified patient recipients.Ken Langone, Chairman of the Board of New York University Langone Health, and Steven Galetta, Chair of Neurology in the School of Medicine, where the authors is senior staff in neuroepidemiology, motivated him to pursue doctoral training in Health Policy and Management. The author has had the good fortune of interacting with thought-provoking medical students, neurology trainees, public health doctoral students, and professors who reinforce the high ethical standards in medical and public health practice and research. However, his patients still educate him in empathy and humanity. The author is grateful to his family, including his spouse Holly and sons Adam and Seth, who serve as his daily compass, encouraging him to take on projects that promote core values of medicine and humanity.

When cannabis tincture was withdrawn from the medical establishment in the UK in 1973, cannabis became regulated solely as an illicit drug. Within a decade cannabis-based drugs were back in the clinic. The UK is one of the biggest producers of medicinal cannabis, but few patients have access to these medicines. High-profile cases of parents campaigning for access to cannabis oil for severe and rare forms of epilepsy in their children are the most recent in a long line of controversies over cannabis and cannabis-based medicines. With mounting questions about patient access, the effectiveness of international drug control systems, and the role of expert advice, it is crucial to understand how we have arrived at this situation. While the historical literature has focused on cannabis as an illicit substance, Remedicalizing Cannabis considers the botanical product and its potential to yield medical applications. Investigating the remedicalization of cannabis, Taylor explores the process whereby boundaries shift between illicit drug and licit medicine. Basing her arguments on archival material from expert committees, researchers, and activists and in-depth interviews with key players, Suzanne Taylor traces the issues and interests involved in this process, demonstrating the important roles of changing scientific knowledge, expert advice, industry, clinical trials, and patient activism. Remedicalizing Cannabis investigates the evolving tensions that have brought us to the current situation and demonstrates the role of history in understanding today’s debates about cannabis.

In Cannabis Pharmacy, expert Michael Backes offers evidence-based information on using cannabis to treat an array of ailments and conditions. He provides information on how cannabis works with the body's own system, how best to prepare and administer it, and how to modify and control dosage. This newly revised edition is now completely up-to-date with the latest information on the body's encannabinoid system, which is now understood to control emotion, appetite, and memory, delivery and dosing of cannabis, including e-cigarette designs, additional varietals, and a new system for classification, as well as 21 additional ailments and conditions that can be treated with medical marijuana. There are currently more than 4.2 million medical cannabis patients in the United States, and there are 29 states plus the District of Columbia where medical cannabis is legal.